These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27518175)

  • 21. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
    Yusuf E; Spapen H; Piérard D
    J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
    Jansen JP; Kumar R; Carmeli Y
    Pharmacoeconomics; 2009; 27(12):1045-56. PubMed ID: 19908928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
    Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis.
    Fawaz S; Barton S; Nabhani-Gebara S
    BMC Infect Dis; 2020 Jun; 20(1):430. PubMed ID: 32563242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic evaluation of piperacillin-tazobactam.
    Hayashi Y; Roberts JA; Paterson DL; Lipman J
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Piperacillin-tazobactam in continuous or expanded perfusion vs intermittent perfusion].
    Acosta García H; Victoria Gil-Navarro M; Cotrina Luque J; Cisneros Herreros JM; Lepe Jiménez JA; Bautista Paloma J
    Farm Hosp; 2012; 36(5):424-9. PubMed ID: 22871367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
    Dietrich ES; Schubert B; Ebner W; Daschner F
    Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.
    Cutro SR; Holzman R; Dubrovskaya Y; Chen XJ; Ahuja T; Scipione MR; Chen D; Papadopoulos J; Phillips MS; Mehta SA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4470-5. PubMed ID: 24867975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
    Kauf TL; Prabhu VS; Medic G; Borse RH; Miller B; Gaultney J; Sen SS; Basu A
    BMC Infect Dis; 2017 Apr; 17(1):314. PubMed ID: 28454524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
    Florea NR; Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
    Am J Health Syst Pharm; 2003 Nov; 60(22):2321-7. PubMed ID: 14652981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
    Paladino JA; Gilliland-Johnson KK; Adelman MH; Cohn SM
    Surg Infect (Larchmt); 2008 Jun; 9(3):325-33. PubMed ID: 18570574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.
    Luther MK; Timbrook TT; Caffrey AR; Dosa D; Lodise TP; LaPlante KL
    Crit Care Med; 2018 Jan; 46(1):12-20. PubMed ID: 29088001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
    Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
    Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
    DeRyke CA; Kuti JL; Mansfield D; Dana A; Nicolau DP
    Am J Health Syst Pharm; 2006 Apr; 63(8):750-5. PubMed ID: 16595817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.